(A) Cause-specific probability of relapse, controlling for the competing risks of treatment failure by nonleukemic causes, among patients with AML transplanted in first or second CR. (B) Cause-specific probability of death, adjusting for the competing risk of leukemic relapse, among patients with AML transplanted in first or second CR. For patients with AML in first CR, the cause-specific probability of regimen-related mortality in the first 100 days after transplant is 9.7% ± 5%.